In murine models of HCC, the combination of VEGF inhibition and PD-1 blockade leads to increased intratumoral CD8+ T cell infiltration and more pronounced tumor regression than either therapy alone [48–50]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.